Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Shares Outstanding (Weighted Average) (2021 - 2025)

Amylyx Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 5 years, most recently at $94.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $94.6 million for Q4 2025, up 38.78% from a year ago — trailing twelve months through Dec 2025 was $94.6 million (up 38.78% YoY), and the annual figure for FY2025 was $94.6 million, up 38.78%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $94.6 million at Amylyx Pharmaceuticals, up from $93.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for AMLX hit a ceiling of $94.6 million in Q4 2025 and a floor of $6.2 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $67.2 million (2023), compared with a mean of $57.6 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): skyrocketed 819.93% in 2022 and later grew 1.18% in 2024.
  • Amylyx Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $6.6 million in 2021, then soared by 788.13% to $58.5 million in 2022, then rose by 14.94% to $67.2 million in 2023, then grew by 1.35% to $68.1 million in 2024, then skyrocketed by 38.78% to $94.6 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $94.6 million (Q4 2025), $93.3 million (Q3 2025), and $87.4 million (Q2 2025) per Business Quant data.